VEGFA and cancer: We speculate that this apparent pro-vascular response to bevacizumab could reflect very low levels of human VEGF in BRAFWT tumors, promoting greater dependency on other compensatory pro-angiogenic mechanisms, such as the recruitment of stromal pro-angiogenic cells including pro-angiogenic bone-marrow-derived cells, macrophages or activated cancer-associated fibroblasts [42–46].